Emcure to buy global rights of chemotherapy brand
Emcure to sell the product through its subsidiaries and its marketing and distribution partners
Mumbai: Emcure Pharmaceuticals Ltd is to acquire worldwide rights for Bristol-Myers Squibb Co.’s BiCNU injection, a chemotherapy agent indicated for treatment of brain tumours, multiple myeloma and a few other types of cancers, for an undisclosed sum.
Under the agreement, Pune-based Emcure will acquire the marketing rights and authorizations, trademarks, technology and the know-how related to the product following a transition period during which US-based Bristol-Myers will continue to distribute the product.
Emcure plans to sell the product through its subsidiaries, including Heritage Pharmaceuticals Inc. in the US, and in some cases through Emcure’s marketing and distribution partners in other markets.
“The acquisition of BiCNU demonstrates Emcure’s commitment to building a leading franchise in the global oncology market," Emcure chief executive officer Satish Mehta said on Tuesday.
The acquisition is expected to increase Emcure’s presence in the global oncology market and serve as an anchor product in building the company’s oncology franchise.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!